134 related articles for article (PubMed ID: 38014458)
1. Bromodomain-containing protein 4 inhibition improves the efficacy of cisplatin and radiotherapy in oral squamous cell carcinoma by suppressing programmed cell death-ligand 1 expression.
Ren J
Basic Clin Pharmacol Toxicol; 2024 Feb; 134(2):272-283. PubMed ID: 38014458
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin-induced HSF1-HSP90 axis enhances the expression of functional PD-L1 in oral squamous cell carcinoma.
Sasaya T; Kubo T; Murata K; Mizue Y; Sasaki K; Yanagawa J; Imagawa M; Kato H; Tsukahara T; Kanaseki T; Tamura Y; Miyazaki A; Hirohashi Y; Torigoe T
Cancer Med; 2023 Feb; 12(4):4605-4615. PubMed ID: 36200687
[TBL] [Abstract][Full Text] [Related]
3. Co-inhibition of BET proteins and PD-L1 as a potential therapy for OSCC through synergistic inhibition of FOXM1 and PD-L1 expressions.
Wang W; Tan J
J Oral Pathol Med; 2019 Oct; 48(9):817-825. PubMed ID: 31177574
[TBL] [Abstract][Full Text] [Related]
4. Expression and clinical value of PD-L1 which is regulated by BRD4 in tongue squamous cell carcinoma.
Zhao L; Li P; Zhao L; Wang M; Tong D; Meng Z; Zhang Q; Li Q; Zhang F
J Cell Biochem; 2020 Feb; 121(2):1855-1869. PubMed ID: 31633227
[TBL] [Abstract][Full Text] [Related]
5. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
[TBL] [Abstract][Full Text] [Related]
6. PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression.
Zhang Z; Sun D; Tang H; Ren J; Yin S; Yang K
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37914384
[TBL] [Abstract][Full Text] [Related]
7. PDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated Glycolysis Signaling Pathway.
Pai S; Yadav VK; Kuo KT; Pikatan NW; Lin CS; Chien MH; Lee WH; Hsiao M; Chiu SC; Yeh CT; Tsai JT
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768921
[No Abstract] [Full Text] [Related]
8. Cisplatin-induced programmed cell death ligand-2 expression is associated with metastasis ability in oral squamous cell carcinoma.
Sudo S; Kajiya H; Okano S; Sasaki M; Katsumata Y; Ohno J; Ikebe T; Hiraki A; Okabe K
Cancer Sci; 2020 Apr; 111(4):1113-1123. PubMed ID: 32012401
[TBL] [Abstract][Full Text] [Related]
9. Co-inhibition of adenosine 2b receptor and programmed death-ligand 1 promotes the recruitment and cytotoxicity of natural killer cells in oral squamous cell carcinoma.
Wang B; Wang T; Yang C; Nan Z; Ai D; Wang X; Wang H; Qu X; Wei F
PeerJ; 2023; 11():e15922. PubMed ID: 37663280
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma.
Shen B; Huang D; Ramsey AJ; Ig-Izevbekhai K; Zhang K; Lajud SA; O'Malley BW; Li D
Br J Cancer; 2020 Mar; 122(5):640-647. PubMed ID: 31853007
[TBL] [Abstract][Full Text] [Related]
11. CMTM6 attenuates cisplatin-induced cell death in OSCC by regulating AKT/c-Myc-driven ribosome biogenesis.
Mohapatra P; Mohanty S; Ansari SA; Shriwas O; Ghosh A; Rath R; Majumdar SKD; Swain RK; Raghav SK; Dash R
FASEB J; 2022 Oct; 36(10):e22566. PubMed ID: 36165231
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L
Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151
[TBL] [Abstract][Full Text] [Related]
13. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
[TBL] [Abstract][Full Text] [Related]
14. BRD4/nuclear PD-L1/RelB circuit is involved in the stemness of breast cancer cells.
Kim SL; Choi HS; Lee DS
Cell Commun Signal; 2023 Nov; 21(1):315. PubMed ID: 37924094
[TBL] [Abstract][Full Text] [Related]
15. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
[TBL] [Abstract][Full Text] [Related]
16. Identification of a Favorable Prognostic Subgroup in Oral Squamous Cell Carcinoma: Characterization of ITGB4/PD-L1
Ma SR; Liu JF; Jia R; Deng WW; Jia J
Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371594
[TBL] [Abstract][Full Text] [Related]
17. Supramolecular nanodrug targeting CDK4/6 overcomes BAG1 mediated cisplatin resistance in oral squamous cell carcinoma.
Zhao B; Qin X; Fu R; Yang M; Hu X; Zhao S; Cui Y; Guo Q; Zhou W
J Control Release; 2024 Apr; 368():623-636. PubMed ID: 38479445
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional factor BRD4 promotes the stemness of esophageal cancer by activating the nuclear PD-L1/RelB axis.
Li S; Guo Q; Guo R; Xu H
Environ Toxicol; 2024 Feb; 39(2):669-679. PubMed ID: 37615218
[TBL] [Abstract][Full Text] [Related]
19. JQ1, a small molecule inhibitor of BRD4, suppresses cell growth and invasion in oral squamous cell carcinoma.
Wang L; Wu X; Huang P; Lv Z; Qi Y; Wei X; Yang P; Zhang F
Oncol Rep; 2016 Oct; 36(4):1989-96. PubMed ID: 27573714
[TBL] [Abstract][Full Text] [Related]
20. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
